A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)

被引：23
|
作者：
Uzzo, Robert
Bex, Axel
Rini, Brian I.
Albiges, Laurence
Suarez, Cristina
Donaldson, Frank
Asakawa, Takashi
Schiff, Christina
Pal, Sumanta K.
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[3] Cleveland Clin, Taussig Canc Insitute, Cleveland, OH 44106 USA
[4] Inst Gustave Roussy, Villejuif, France
[5] Vall dHebron Univ Hosp Inst Oncol VHIO, Barcelona, Spain
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[8] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS4598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4598
引用
收藏
页数：5
相关论文
共 50 条
  • [1] IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
    Bex, A.
    Uzzo, R.
    Karam, J. A.
    Master, V. A.
    Donskov, F.
    Suarez, C.
    Albiges, L.
    Rini, B. I.
    Tomita, Y.
    Kann, A.
    Procopio, G.
    Massari, F.
    Zibelman, M.
    Antonyan, I.
    Huseni, M.
    Basu, D.
    Ci, B.
    Leung, W.
    Khan, O.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1431 - S1432
  • [2] Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection
    Albiges, Laurence
    Bex, Axel
    Suarez, Cristina
    Uzzo, Robert
    Tang, Xiaobin
    Assaf, Zoe June
    Dubey, Sarita
    Goluboff, Erik T.
    Carter, Corey
    Banchereau, Romain
    Huseni, Mahrukh A.
    Pal, Sumanta Kumar
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
    Khene, Zine-Eddine
    Borchiellini, Delphine
    Bensalah, Karim
    EUROPEAN UROLOGY, 2023, 83 (05) : 475 - 476
  • [4] Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
    Pal, Sumanta Kumar
    Uzzo, Robert
    Karam, Jose Antonio
    Master, Viraj A.
    Donskov, Frede
    Suarez, Cristina
    Albiges, Laurence
    Rini, Brian
    Tomita, Yoshihiko
    Kann, Ariel Galapo
    Procopio, Giuseppe
    Massari, Francesco
    Zibelman, Matthew
    Antonyan, Igor
    Huseni, Mahrukh
    Basu, Debasmita
    Ci, Bo
    Leung, William
    Khan, Omara
    Dubey, Sarita
    Bex, Axel
    LANCET, 2022, 400 (10358): : 1103 - 1116
  • [5] Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
    Wu, Zhenjie
    Wang, Linhui
    Pandolfo, Savio D.
    Autorino, Riccardo
    EUROPEAN UROLOGY, 2023, 83 (03) : 297 - 298
  • [6] Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
    Karam, Jose Antonio
    Uzzo, Robert
    Bex, Axel
    Leung, William
    Tat, Connie
    Nicholas, Alan
    Andreev-Drakhlin, Alexander
    Huseni, Mahrukh
    Pal, Sumanta Kumar
    Master, Viraj A.
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (06): : 1175 - 1178
  • [7] Adjuvant Therapy of Renal Cell Carcinoma with high Risk of Recurrence after Nephrectomy A randomized, multicentre, Placebo-controlled, double-blind Phase III Study of Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy for Patients with Renal Cell Carcinoma and a high Recurrence Risk after Nephrectomy (IMmotion010) - AN 42/16 of AUO
    Rexer, H.
    Doehn, C.
    Gruellich, C.
    UROLOGE, 2018, 57 (05): : 643 - 644
  • [8] IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
    Atkins, Michael B.
    McDermott, David F.
    Powles, Thomas
    Motzer, Robert J.
    Rini, Brian I.
    Fong, Lawrence
    Joseph, Richard Wayne
    Pal, Sumanta K.
    Sznol, Mario
    Hainsworth, John D.
    Stadler, Walter Michael
    Hutson, Thomas E.
    Ravaud, Alain
    Bracarda, Sergio
    Suarez, Cristina
    Choueiri, Toni K.
    Qiu, Jiaheng
    Huseni, Mahrukh A.
    Schiff, Christina
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
    Wakelee, Heather A.
    Altorki, Nasser K.
    Vallieres, Eric
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Sandler, Alan
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
    Wong, Deborah J.
    Fayette, Jerome
    Teixeira, Maria
    Prabhash, Kumar
    Mesia, Ricard
    Kawecki, Andrzej
    Dechaphunkul, Arunee
    Dinis, Jose
    Guo, Ye
    Masuda, Muneyuki
    Hsieh, Ching-Yun
    Ghi, Maria Grazia
    Sette, Claudia Vaz de Melo
    Jiang, Tao
    Yan, Yibing
    Kaul, Monika
    Jagtiani, Ritika
    Matheny, Christina
    Cuchelkar, Vaikunth
    Haddad, Robert
    CANCER RESEARCH, 2024, 84 (07)
12345